We are live on ! Find out more
EWTX icon

Edgewise Therapeutics

174 hedge funds and large institutions have $1.82B invested in Edgewise Therapeutics in 2025 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 58 increasing their positions, 62 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

90% more call options, than puts

Call options by funds: $3.84M | Put options by funds: $2.02M

6% less repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 62

2% less funds holding

Funds holding: 178 → 174 (-4)

6.54% less ownership

Funds ownership: 112.87% → 106.33% (-6.5%)

18% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 22

25% less funds holding in top 10

Funds holding in top 10: 8 → 6 (-2)

63% less capital inflows, than outflows

Capital inflows: $54.9M | Capital outflows: $148M

Holders
174
Holders Change
-4
Holders Change %
-2.25%
% of All Funds
2.27%
Holding in Top 10
6
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-25%
% of All Funds
0.08%
New
18
Increased
58
Reduced
62
Closed
22
Calls
$3.84​M
Puts
$2.02​M
Net Calls
+$1.82​M
Net Calls Change
+$2.2​M

EWTX Hedge Fund Activity: Q3 2025 in Review

174 of the 7,665 institutional investors tracked by Wall St. Rank reported a position in Edgewise Therapeutics (EWTX) for Q3 2025, worth a combined $1.82B — up 17% from $1.56B a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of EWTX and 18 opened new positions — a net loss of 4 holders — while 62 trimmed existing stakes and 58 added.

The largest buyer was Siren LLC, adding an estimated $10.5M. The largest seller was Deerfield Management, cutting an estimated $18.5M.

  • 174 institutional investors held Edgewise Therapeutics (EWTX) as of Q3 2025, down from 178 in Q2 2025.
  • Funds reported $1.82B of Edgewise Therapeutics stock for Q3 2025, up 17% quarter-over-quarter.
  • 18 funds opened new Edgewise Therapeutics positions in Q3 2025 and 22 closed out, a net change of -4 holders.
  • The largest Edgewise Therapeutics buyer in Q3 2025 was Siren LLC, an estimated $10.5M added.
  • The largest Edgewise Therapeutics seller in Q3 2025 was Deerfield Management, an estimated $18.5M sold.

Based on aggregated 13F filings for Q3 2025.